Showing results (61-70 of 139) with videos related to
Sort By:
Pageof 14
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 23, 2014
Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studiesDuleeka W Knipe, David M Evans, John P Kemp, et al.The Lancet. Oncology|March 3, 2006
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studySusan M Domchek, Tara M Friebel, Susan L Neuhausen, et al.Cancer Research|December 14, 2021
Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer RiskRick A C M Boonen, Wouter W Wiegant, Nandi Celosse, et al.European Urology|June 25, 2018
Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic AetiologyChey Loveday, Philip Law, Kevin Litchfield, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2022
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate CancerTommy Nyberg, Mark N Brook, Lorenzo Ficorella, et al.Endocrine-Related Cancer|January 7, 2015
HES5 silencing is an early and recurrent change in prostate tumourigenesisCharles E Massie, Inmaculada Spiteri, Helen Ross-Adams, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.Nature Genetics|May 14, 2013
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14Elise Ruark, Sheila Seal, Heather McDonald, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley, Kate McReynolds, Audrey Ardern-Jones, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 14, 2006
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriersDeborah Thompson, Sheila Seal, Mieke Schutte, et al.Pageof 14